diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 329db7879..6aef0237c 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -19,22 +19,28 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric ### Additional Evidence (extend) -*Source: [[2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations]] | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5* +*Source: 2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations | Added: 2026-03-15 | Extractor: anthropic/claude-sonnet-4.5* Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients. ### Additional Evidence (extend) -*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15* +*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15* The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category. ### Additional Evidence (extend) -*Source: [[2025-03-01-medicare-prior-authorization-glp1-near-universal]] | Added: 2026-03-15* +*Source: 2025-03-01-medicare-prior-authorization-glp1-near-universal | Added: 2026-03-15* MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems. + +### Additional Evidence (extend) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Trump Administration's November 2025 Medicare deal establishes $245/month pricing for semaglutide and tirzepatide (82% below list price) with narrow eligibility criteria requiring comorbidities, not just obesity. This dramatically changes the economics analyzed in the original claim: the 'inflationary through 2035' conclusion assumed higher prices (~$1,000+/month) and potentially broader population coverage. The narrow targeting (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD) limits the eligible Medicare population to ~10% of beneficiaries — those where downstream savings are most likely. Under MA capitation, this targeted approach may actually be cost-effective at the plan level even if system-level impact remains inflationary. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1f412e7f8..5141f9485 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design. + +### Additional Evidence (extend) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2026 for tirzepatide) removes most financial barriers to persistence in the Medicare population. The existing claim about 15% two-year persistence was driven partly by affordability — the Trump deal's dramatic cost reduction ($50 OOP vs. previous $1,000+/month) may improve persistence rates specifically in the Medicare population, though this remains to be tested. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index c8aa03417..5638804dd 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se. + +### Additional Evidence (confirm) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Trump Administration's Medicare deal establishes $50/month out-of-pocket maximum for beneficiaries, explicitly targeting affordability as a persistence barrier. The deal structure (manufacturer concessions to achieve low OOP costs) confirms that policymakers recognize affordability as a primary driver of discontinuation, not just clinical factors. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json new file mode 100644 index 000000000..febfc583b --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "narrow-eligibility-targeting-in-glp-1-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-cms-rulemaking.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "narrow-eligibility-targeting-in-glp-1-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md:set_created:2026-03-16", + "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-cms-rulemaking.md:set_created:2026-03-16" + ], + "rejections": [ + "narrow-eligibility-targeting-in-glp-1-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md:missing_attribution_extractor", + "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-cms-rulemaking.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md index 4b112ae56..5d05521be 100644 --- a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md +++ b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md @@ -7,9 +7,13 @@ date: 2025-11-06 domain: health secondary_domains: [internet-finance] format: news -status: unprocessed +status: enrichment priority: high tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -45,3 +49,14 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage + + +## Key Facts +- Medicare GLP-1 payment demonstration begins July 2026 +- BALANCE Model in Medicaid launches May 2026 +- BALANCE Model in Medicare Part D begins January 2027 +- Oral Wegovy launches January 2026 at $149-$299/month +- Estimated 10% of Medicare beneficiaries eligible under the narrow criteria +- Medicare/Medicaid price: $245/month for semaglutide and tirzepatide +- TrumpRx general price: $350/month (down from ~$1,350/month injectable) +- Medicare beneficiary OOP maximum: $50/month for tirzepatide starting April 2026